Caitlyn Mourcos
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Caitlyn Mourcos has a total of 16 co-authors. Here are the top co-authors by number of shared publications:
- Alva Annett
Department of Human Genetics, McGill University, Montreal, Canada
1 shared publication - Anna-Maria Lazaratos
Rosalind and Morris Goodman Cancer Institute, Montreal, QC H3T 1E2, Canada
1 shared publication - Caitlynn Mirabelli
Lady Davis Institute for Medical Research, Jewish General Hospital, Montréal, QC, Canada
1 shared publication - Claudia L. Kleinman
Lady Davis Research Institute, Jewish General Hospital, Montréal, Canada
1 shared publication - Elias Maldonado
Division of Clinical and Translational Research, McGill University, Montreal, Canada
1 shared publication - Forest M. White
Department of Biological Engineering, Massachusetts Institute of Technology
1 shared publication
Latest Publications
- Open Access
- 11 July 2025
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 11 (28) , eadu5915
Complex I inhibition combined with TLR activation in the breast tumor microenvironment educates cytotoxic neutrophils
Although effective for immunologically hot tumors, immune checkpoint inhibitors minimally affect tumors that are not T cell inflamed, including breast cancer. An alternate strategy to combat immune cold breast tumors may be to reeducate innate immunity. This study identifies strategies to skew neutrophils to acquire tumoricidal properties. Systemic Toll-like receptor (TLR)–induced inflammation, concomitant with mitochondrial complex I inhibition in breast tumors, increases neutrophil cytotoxicity against breast cancer cells and independently of CD8+ T cell immunity. These therapy-entrained neutrophils enhance secretory granule production, increasing expression of the reduced form of nicotinamide adenine dinucleotide phosphate (NADPH) oxidase machinery and inducing a respiratory burst. Moreover, systemic administration of TLR agonists elevates nuclear factor κB signaling in neutrophils to increase production of secretory granule and NADPH oxidase machinery components, whereas complex I inhibitors are required to potentiate oxidative damage. In summary, we describe a class of neutrophils, educated by the combined action of inflammatory mediators and metabolic inhibitors, having tumoricidal functions.
- 11 July 2025
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 11 (28) , eadu5915
Open AccessComplex I inhibition combined with TLR activation in the breast tumor microenvironment educates cytotoxic neutrophils
Although effective for immunologically hot tumors, immune checkpoint inhibitors minimally affect tumors that are not T cell inflamed, including breast cancer. An alternate strategy to combat immune cold breast tumors may be to reeducate innate immunity. This study identifies strategies to skew neutrophils to acquire tumoricidal properties. Systemic Toll-like receptor (TLR)–induced inflammation, concomitant with mitochondrial complex I inhibition in breast tumors, increases neutrophil cytotoxicity against breast cancer cells and independently of CD8+ T cell immunity. These therapy-entrained neutrophils enhance secretory granule production, increasing expression of the reduced form of nicotinamide adenine dinucleotide phosphate (NADPH) oxidase machinery and inducing a respiratory burst. Moreover, systemic administration of TLR agonists elevates nuclear factor κB signaling in neutrophils to increase production of secretory granule and NADPH oxidase machinery components, whereas complex I inhibitors are required to potentiate oxidative damage. In summary, we describe a class of neutrophils, educated by the combined action of inflammatory mediators and metabolic inhibitors, having tumoricidal functions.